- Home
- PPBT vs INM Comparison
PPBT vs INM Comparison
Compare PPBT & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- INM
- Stock Information
- Founded
- PPBT 2010
- INM 1981
- Country
- PPBT Israel
- INM Canada
- Employees
- PPBT N/A
- INM N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- INM Health Care
- Exchange
- PPBT Nasdaq
- INM Nasdaq
- Market Cap
- PPBT 5.5M
- INM 5.0M
- IPO Year
- PPBT N/A
- INM N/A
- Fundamental
- Price
- PPBT $0.59
- INM $2.07
- Analyst Decision
- PPBT Strong Buy
- INM
- Analyst Count
- PPBT 1
- INM 0
- Target Price
- PPBT $33.00
- INM N/A
- AVG Volume (30 Days)
- PPBT 234.5K
- INM 116.2K
- Earning Date
- PPBT 11-14-2025
- INM 11-13-2025
- Dividend Yield
- PPBT N/A
- INM N/A
- EPS Growth
- PPBT N/A
- INM N/A
- EPS
- PPBT N/A
- INM N/A
- Revenue
- PPBT N/A
- INM $4,942,633.00
- Revenue This Year
- PPBT N/A
- INM N/A
- Revenue Next Year
- PPBT N/A
- INM N/A
- P/E Ratio
- PPBT N/A
- INM N/A
- Revenue Growth
- PPBT N/A
- INM 7.50
- 52 Week Low
- PPBT $0.53
- INM $1.72
- 52 Week High
- PPBT $13.95
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- PPBT 29.54
- INM 42.37
- Support Level
- PPBT $0.56
- INM $2.04
- Resistance Level
- PPBT $0.66
- INM $2.26
- Average True Range (ATR)
- PPBT 0.04
- INM 0.14
- MACD
- PPBT 0.05
- INM -0.01
- Stochastic Oscillator
- PPBT 29.11
- INM 10.44
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.